Background
==========

Globally, vitamin A deficiency (VAD) affects 100--140 million children, 4.4 million of whom have xerophthalmia \[[@B1],[@B2]\]. Coverage rates for full vitamin A supplementation (VAS) of children 6--59 months delivered through primary care have risen significantly over the last decade, reaching 88% for the least developed countries \[[@B3]\]. In recent years, alternative strategies to improve micronutrient nutrition have been increasingly applied for high-risk populations already supplemented with vitamin A (VA): micronutrient powders; fortification of staple foods; ready-to-use supplemental and therapeutic foods (RUSF and RUTF); and other food-based approaches.

Among the populations particularly vulnerable to VAD are children with severe acute malnutrition (SAM) \[[@B4]\]. The World Health Organization (WHO) currently recommends that for inpatient care of children with SAM, VA supplements be given on day 1 of admission unless there is clear evidence that VA was received in the last month \[[@B5]\]. Dosing guidelines are the following: 200,000 international units (IU) for children over 12 months of age, 100,000 IU for children 6--12 months, and 50,000 IU for children below 6 months. If clinical signs of vitamin A deficiency are present, then another age-specific, large dose is administered on day 2 and again, on day 14 \[[@B4],[@B5]\]. Low-dose VA is then given as part of a vitamin mix added to F-75 or F-100 therapeutic milk formulations, or alternatively, as a proprietary multivitamin supplement or combined mineral-vitamin mix (CMV). There is a need to revisit these guidelines in the context of improved VA availability, but also in view of evidence showing the potential for harmful effects of such VAS dosages \[[@B6]\].

Methods
=======

This systematic review aimed to assess the safety and effectiveness of VAS in children with SAM, with regards to mortality, nutritional recovery, and signs of symptomatic VAD \[[@B7]\]. A literature review was undertaken to search for all randomized controlled trials (RCT) and observational studies published from 1950 to March 2012. Databases searched included MEDLINE, EMBASE, and Google Scholar. The clinical trial registries at clinicaltrials.gov, pactr.org, and apps.who.int/trialsearch were also searched. Initial key words for the searches included "malnutrition", "severe malnutrition", "kwashiorkor", "marasmus", "vitamin A", and "retinol". A number of outcome measures were sought, including mortality, weight gain, nutritional recovery, and VAD. Further terms were added iteratively to the search based on results obtained from the initial searches.

Searches were also conducted to identify relevant publications and study documents produced by international health organizations such as the WHO and UNICEF. The titles and abstracts were scanned to identify relevant studies. The full text of relevant studies was obtained and the list of articles for inclusion further optimized based on an evaluation of the full text. Reference lists in relevant articles were also scanned manually and electronically to identify other studies that may have been missed in the original searches. Relevant publications that cited those previously identified articles were similarly sought.

Studies were included for full review based on relevance to the population of interest, study interventions, study design, outcome measures, and an assessment of the study's methodological rigor and quality. These studies were then assessed and entered into a Grading of Recommendations, Assessment, Development and Evaluation (GRADE) table summarizing design, aim, outcomes, GRADE criteria assessment (indirectness, inconsistency, imprecision, and study limitations), and quality ranking (high, moderate, or low) \[[@B8]\].

*Indirectness* was judged based on study relevance to the review question in terms of the study population (children with SAM), intervention of interest (VAS), and outcome measures (mortality, recovery from SAM, signs of symptomatic VAD, and adverse outcomes due to supplementation) \[[@B9]\]. Consideration was given under this category to VA dosing relative the WHO protocol. *Inconsistency* was assessed by comparing point estimates and examining the heterogeneity of methods and statistical analyses \[[@B10]\]. *Imprecision* was based primarily on the 95% confidence interval with consideration of effect and sample sizes \[[@B11]\]. Potential biases (selection, recall, information/observation, misclassification) arising from failure to blind, losses in follow-up, inappropriate controls, and failure to adjust for confounding factors, among other problems, were considered under the *study limitations (risk of bias)* criteria \[[@B12]\].

Once these criteria were assessed, each study was assigned a quality ranking ranging from low to high. Only those studies with some degree of moderate or high (*i.e.*, low-moderate, moderate, moderate-high, or high) quality ranking were included in this review for consideration in making recommendations on the use of VAS for the treatment of children with SAM.

Results
=======

Of the 2072 abstracts identified and screened, 38 were selected for full review (Figure [1](#F1){ref-type="fig"}). Twenty-two were of moderate- to high-quality, and were grouped into 3 categories and listed primary outcomes assessed: 1) previous reviews; 2) observational studies; and 3) randomized controlled trials (RCT).

![**Flow diagram for studies included in review.** The figure presents a flow diagram detailing the number of records screened and excluded, full-text articles reviewed, and ultimately, the number of studies included in the systematic review. The included observational and RCT studies are enumerated according to the primary outcome examined.](1475-2891-12-125-1){#F1}

Previous reviews
----------------

Two previous reviews of VAS trials were identified; both considered malnourished children together with those not malnourished \[[@B7],[@B13]\]. Preventive VAS reduced all-cause mortality by 25% and diarrhea-specific mortality by 30%. VA showed greater protection against morbidity and mortality in Asia than in Africa or Latin America \[[@B13]\]. An earlier review found that the severity of measles and diarrheal infections were reduced by VAS, but the risk of lower respiratory tract infection was increased in some trials \[[@B7]\]. Because the reviews did not provide new evidence for VA and management of SAM and all studies from the reviews were screened for this review, they were not included in the GRADE assessment.

Observational studies
---------------------

Five observational studies were identified and assigned a GRADE quality ranking of low to moderate \[[@B14]-[@B18]\] (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). These studies found significant associations between serum or plasma retinol concentrations and SAM \[[@B14]-[@B16]\]. Others established a link between VAD, SAM, and diarrhea. In Bangladesh, reduced serum retinol concentrations were associated with shigellosis and low weight-for-age Z-score \[[@B18]\]. Another case--control study in Bangladesh showed that the duration of diarrhea and SAM were independently associated with xerophthalmia \[[@B17]\].

Randomized controlled trials
----------------------------

Fifteen RCTs of moderate to high quality based on GRADE criteria were included in the systematic review on the safety and efficacy of high-dose VAS in children with SAM (Table [1](#T1){ref-type="table"}). Issues of *indirectness* were present in all trials. Only one trial included children with SAM exclusively \[[@B19]\]. The remaining 14 included non-malnourished and malnourished children \[[@B20]-[@B33]\]. VA dosing also varied; only five trials administered the recommended high-dose on day 1 \[[@B19],[@B26],[@B30],[@B31],[@B33]\], while the remaining administered VA doses in varying quantities and forms. Only one trial followed the WHO protocol \[[@B19]\]; two compared high dose with daily low dose \[[@B26],[@B33]\], and the remaining 12 compared high dose VAS with placebo \[[@B20]-[@B25],[@B27]-[@B32]\].

###### 

Randomized controlled trials included in the systematic review

  **Quality Assessment**               **Summary of Findings**                                                                                                                                                                       **GRADE Rating**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  ------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ------------------------------- ------------ ----------
  Sattar, 2012 \[[@B19]\]              RCT, double-blind                                                                                                                                                                             Pop: children 6-59 mo with SAM and diarrhea and/or ALRI                                                                                                       SAM def: WHZ \< -3 or bipedal edema                                                                                                        No serious imprecision                                                                              No differences in baseline characteristics                                                                              High-dose and daily low-dose VA (n = 130)                                                                                              Daily low-dose VA (n = 130)                                                                    MOD-HIGH
                                       Aim: test the efficacy and safety of WHO protocol for VAS in treatment of SAM among children 6-59 mo                                                                                          VA dose: day 1: high-dose group, 200,000 IU (\> 12 mo) or 100,000 IU (\< 12 mo); low-dose group, placebo; day 2-15, 5000 IU daily for 15 days (both groups)                                                                                                                                                                                                                                                  External validity: all children had diarrhea and low mean baseline serum retinol 13.15 ± 9.28 ug/dl                     Resolution by 48 hr of acute diarrhea, dysentery, and ALRI                                                                                                                                                               NS            
                                                                                                                                                                                                                                     Secondary outcome examined and found no increased risk of adverse events VA toxicity and morbidities.                                                                                                                                                                                                                                                                                                                                                                                                                                Duration of acute diarrhea, invasive diarrhea, cough, fever, rales, edema, and skin changes                                                                                                                              NS            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Changes in nutritional status, weight, length, MUAC, head circumference                                                                                                                                                  NS            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Incidence of nosocomial diarrhea                                                                                                                                                         aOR 1.25 (0.67, 2.34)           NS            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          and ALRI infections                                                                                                                                                                      aOR 0.63 (0.36-1.09)            NS            
  Donnen, 2007 \[[@B33]\]              RCT, double-blind                                                                                                                                                                             Pop: 44-48% WHZ \< -2; 30-37% MUAC \< 125 mm                                                                                                                  SAM def: WHZ \< -2; MUAC \< 125 mm                                                                                                         No serious imprecision                                                                              Age confounding: high-dose group younger                                                                                Daily low-dose VA (n = 610)                                                                                                            Single high-dose VA and placebo daily (n = 604)                                                MOD
                                       Aim: assess effect of single high-dose vs. daily low-dose VA supplements on hospitalized malnourished Senegalese children's (0 - 14 yr) morbidity                                             VA dose: high-dose: single 200,000 IU (\> 12 mo) or 100,000 IU (\< 12 mo); low-dose: 5000 IU daily until discharge                                                                                                                                                                                                                                                                                           Baseline nutrition: MUAC lower in high-dose group                                                                       Incidence of respiratory disease                                                                                                                                                         HR 0.26 (0.07 - 0.92)           p \< 0.05     
                                                                                                                                                                                                                                     Sub-group: children with edema mortality lower in low-dose (AOR 0.21, 0.05-0.99)                                                                                                                                                                                                                                                                                                                                                                                                                                                     Duration: respiratory disease                                                                                                                                                            HR of cure 1.41 (1.05 - 1.89)   p = 0.019     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Incidence & duration of diarrhea                                                                                                                                                         HR 1.02 (0.68 - 1.52)           NS            
  Mahalan-abis, 2004 \[[@B32]\]        RCT, factorial                                                                                                                                                                                Pop: children with marasmus or edema excluded                                                                                                                 No serious inconsistency                                                                                                                   Small sample                                                                                        Baseline nutrition: serum retinol was 0.387 μmol/L higher (P = 0.001) in VA treated group                               zinc + VA (n = 38) zinc (n = 39) VA (n = 38)                                                                                           Placebo (n = 38)                                                                               LOW-MOD
                                       Aim: evaluate effect of zinc and VA on clinical recovery of Indian children (2 - 24 mo) with severe acute lower respiratory infections                                                        VA dose: 10,000 μg RE 2x/d for 4d; zinc 10 mg 2x/d for 5d                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Recovery rates from very ill status zinc (boys)                                                                                                                                          2.63 (1.35 - 5.10)                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Recovery rate from fever zinc                                                                                                                                                            3.12 (1.47 - 6.6)               NS            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Recovery rates for VA                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Adverse event risk** increased risk of diarrhea in VA group                                                                                                                                                            p = 0.028     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          increased risk of any adverse events in VA group                                                                                                                                         RR 3.8 (1.32-10.93)                           
  Fawzi, 2000 \[[@B31]\]               RCT                                                                                                                                                                                           VA dose: given on days 0 and 2, and again at 4 and 8 mo; dose after discharge, 200,000 IU (\> 1 yr) or 100,000 IU (infants)                                   SAM def: NCHS references; WHZ \< -2                                                                                                        Statistics: few variables studied in multivariate analyses                                          Potential seasonal bias: enrollment during 1993-1997                                                                    VA (n = 289)                                                                                                                           Placebo (n = 285)                                                                              LOW-MOD
                                       Aim: determine effect of VAS on risk of diarrhea and acute respiratory infections in hospitalized Tanzanian children (6 - 60 mo)                                                              Sub-group: **adverse event risk** normally nourished children: VA increased risk of acute diarrhea; wasted children protective against diarrhea               Diarrhea def: mother's perception; 3+ days elapsed between episode; persistent diarrhea defined as lasting 14+ days                                                                                                                                                                                                                                                    Severe watery diarrhea                                                                                                                                                                   AOR 0.56 (0.32 - 0.99)                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Hospitalization                                                                                                                                                                                                          NS            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Adverse event risk** cough and rapid respiratory rate                                                                                                                                  AOR 1.67 (1.17 - 2.36)                        
  Faruque, 1999 \[[@B29]\]             RCT, factorial                                                                                                                                                                                Pop: 34-35% WAZ \< -2; acute diarrhea ≤ 3 days                                                                                                                Diarrhea def: mother's perception with picture                                                                                             No serious imprecision                                                                              No differences observed by stunting at baseline                                                                         Group A: VA 15d (n = 170) Group B: zinc (n = 172) Group C: VA + zinc (n = 171)                                                         Placebo (n = 171)                                                                              MOD
                                       Aim: to assess efficacy of zinc or VAS in Bangladeshi children (6 mo - 2 yr) with acute diarrhea                                                                                              VA dose: 4500 μg RE for 15d                                                                                                                                   Children observed in hospital 24 h and followed at home 15d                                                                                                                                                                                                                                                                                                            Zinc groups Diarrhea duration reduced by 13 %                                                                                                                                                                            p = 0.03      
                                                                                                                                                                                                                                     Zinc dose: 14.2 - 40 mg zinc for 15d                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Prolonged diarrhea reduced by 43%                                                                                                                                                                                        p = 0.017     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          VA groups Prolonged diarrhea                                                                                                                                                                                             NS            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Overall diarrhea duration                                                                                                                                                                                                NS            
  Donnen, AJCN 1998 \[[@B26]\]         RCT, double-blind                                                                                                                                                                             Pop: 26-28% WHZ \< -2; 20-29% MUAC \< 125 mm                                                                                                                  SAM def: WHZ \< -2, MUAC \< 125 mm                                                                                                         Small effect size                                                                                   Baseline CRP elevated in high dose group                                                                                Daily low-dose VA (n = 298)                                                                                                            High-dose VA (n = 300)                                                                         MOD
                                       Aim: assess effect of single high-dose vs. daily low-dose VA supplements on hospitalized pre-school aged children in Democratic Republic of Congo                                             VA dose: high-dose: single 200,000 IU (\> 12 mo) or 100,000 IU (\< 12 mo) at admission; low-dose: 5000 IU daily until discharge                                                                                                                                                                                                                                                                                                                                                                                                      Sub-group: SAM (low dose VA vs. placebo) Incidence of severe diarrhea in SAM                                                           Placebo (n = 302)                                 RR 0.21(0.07 - 0.62)                          
                                                                                                                                                                                                                                     **Adverse event risk** Sub-group: children with no edema increased risk of diarrhea with high-dose VA compared to placebo (AOR 2.42, 1.15 - 5.11)                                                                                                                                                                                                                                                                                                                                                                                    Duration of: severe diarrhea                                                                                                                                                                                             NS            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Acute lower respiratory infection                                                                                                                                                                                        NS            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Fever                                                                                                                                                                                                                    NS            
  Donnen, J of Nutr. 1998 \[[@B20]\]   RCT                                                                                                                                                                                           VA dose: 60 mg oily solution of retinyl palmitate (30 mg for children \< 12 mo)                                                                               SAM def: WHZ \< -2, MUAC \< 125 mm; NCHS standards; discharged children                                                                                                                                                                        Failure to blind: no placebo used                                                                                       Group 1: VA baseline and at 6 mo (n = 118)                                                                                             Group 3: placebo (n = 117)                                                                     MOD
                                       Aim: assess effect of single high-dose VA supplements and regular antiparasitic therapy on growth of moderately malnourished children (0 - 72 mo) from eastern Zaire                          Pop: 4-9% WHZ \< -2                                                                                                                                                                                                                                                                                                                                                                                          Unclear why changes in Z-scores not compared                                                                            Group 2: Mebendazole every 3 mo for 1 yr (n = 123)                                                                                                                                                                                     
                                                                                                                                                                                                                                     Sub-group: VA boys gain more weight and height                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Group 1: Annual weight gain 2.09 kg                                                                                                    Group 3: Annual weight gain 1.18 kg                                               p = 0.029     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          MUAC gain 2.24 cm                                                                                                                      MUAC gain 0.95 cm                                                                 p = 0.012     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Group 2 vs. 3 Growth                                                                                                                                                                                                     NS            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Adverse risk:** VA girls gained less height than controls. De-wormed boys and girls gained less weight than control boys and girls                                                                                                   
  Stephen-sen, 1998 \[[@B28]\]         RCT, double-blinded                                                                                                                                                                           VA dose: children ≤ 1 yr: 100,000 IU on day 1 and 50,000 IU on day 2; children \> 1 yr: 200,000 IU on day 1 and 100,000 IU on day 2                           SAM def: US reference population                                                                                                           Small sample                                                                                        Potential confounding: WHZ lower in VA group at baseline                                                                VA (n = 48)                                                                                                                            Placebo (n = 49)                                                                               LOW-MOD
                                       Aim: test hypothesis that high-dose VA supplements will enhance recovery of Peruvian children (3 mo - 10 yrs) hospitalized with pneumonia                                                                                                                                                                                                                                                                                                                                                              Statistics: univariate comparisons reported primarily without adjusting for covariates              Selective reporting                                                                                                     **Adverse events:** ↓ blood oxygen saturation                                                                                          **Adverse events:** ↑blood oxygen saturation                                      p \< 0.05     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Prevalence of retractions 37%                                                                                                          Prevalence of retractions 15%                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Auscultatory evidence of consolidation 28%                                                                                             Auscultatory evidence of consolidation 17%                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          supplemental oxygen need 21%                                                                                                           supplemental oxygen need 8%                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Duration of hospitalization                                                                                                                                                                                              NS            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Chest x-rays                                                                                                                                                                                                             NS            
  Nacul, 1997 \[[@B24]\]               RCT, double-blind placebo                                                                                                                                                                     VA dose: 200,000 IU (\< 12 mo); 400 000 IU (\> 12 mo)                                                                                                         Pop: some hospitalized while others outpatient                                                                                             No serious imprecision                                                                              Low serum retinol at baseline in both groups likely due to infection; serum retinol in VA group higher on day 11        VA (n = 239)                                                                                                                           Placebo (n = 233)                                                                              MOD-HIGH
                                       Aim: evaluate impact of VAS on clinical recovery and severity of pneumonia among Brazilian children (6 - 59 mo)                                                                               Subgroup analysis showed beneficial effect on those most severely affected with VA deficiency                                                                                                                                                                                                                                                                                                                                                                                                                                        Fever by day 3: 16 %                                                                                                                   Fever by day 3: 26.4 %                                                            p = 0.008     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Transitory bulging fontanelle (4%)                                                                                      Failure to respond to first line antibiotic                                                                                                                                              rate ratio 0.71 (0.50 - 1.01)   p = 0.054     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No effect attributable to etiological agent                                                                             Duration of pneumonia                                                                                                                                                                                                    NS            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Incidence of adverse outcomes                                                                                                                                                                                            NS            
  Julien, 1999 \[[@B30]\]              RCT, double-blind placebo                                                                                                                                                                     VA dose: 200,000 IU (\>12 mo); 100,000 IU (\< 12 mo)                                                                                                                                                                                                                                                     Small sample size to detect morbidity differences                                                   VA deficiency high at baseline in both groups: 68.9% had serum retinol \<10 μg/dL and 93.2% serum retinol \< 20 μg/dL   VA (n = 71)                                                                                                                            Placebo (n = 93)                                                                               LOW-MOD
                                       Aim: test the potential of VAS at admission to speed up recovery during hospitalization for lower respiratory infection and decrease morbidities at 6 wk in Mozambican children (6 - 72 mo)   Pop: kwashiorkor and marasmus excluded                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Rate of clinical discharge on day 5: 88.4%                                                                                             Rate of clinical discharge on day 5: 73.9%        RR 1.9 (1.01 - 3.05)            NS            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No adjustment with covariates                                                                                           6 wk Health care use Illness (fever, cough, or diarrhea)                                                                                                                                                                 NS            
  Hossain, 1998 \[[@B27]\]             RCT, double-blind                                                                                                                                                                             Pop: excluded if WAZ ≤75% NCHS                                                                                                                                Diarrhea def: liquid stools that can be poured or contain blood or mucus; clinical cure: ≤3 formed stools without visible blood or mucus   Small sample size                                                                                   Baseline VA status not determined, but population prevalence high                                                       VA (n = 42)                                                                                                                            Control (n = 41)                                                                               LOW-MOD
                                       Aim: evaluate efficacy of single oral dose VA in treating shigellosis among Bangladeshi children (1 - 7 yr)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                No adjustment with covariates                                                                                           Clinical cure 19/24 (45%)                                                                                                              Clinical cure 8/14 (20%)                          risk ratio 0.68 (0.50 - 0.93)   p = 0.02      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Bacteriological cure 16/42 (38%)                                                                
                                                                                                                                                                                                                                     Bacteriological cure 16/41 (39%)                                                                                                                              risk ratio 0.98 (0.70 - 1.39)                                                                                                              NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Si, 1997 \[[@B25]\]                  RCT, double-blind                                                                                                                                                                             Pop: SAM excluded; 45% moderately underweight                                                                                                                 Nutrition def: moderate malnutrition defined as WAZ 60-80% of NCHS median                                                                  No confidence intervals provided                                                                    Potential selection bias: trend for greater pneumonia severity in VA group (p = 0.06)                                   VA (n = 280)                                                                                                                           Placebo (n = 312)                                                                 NS           LOW-MOD
                                       Aim: evaluate effect of high dose VA supplement on morbidity in hospitalized Vietnamese children (1 - 59 mo) with pneumonia                                                                   VA dose: 200,000 in peanut oil (\< 1 yr); 400,000 IU in peanut oil (1 - 4 yr)                                                                                                                                                                                                                                                                                                                                No baseline VA status                                                                                                   Mean time to normal: fever respiratory rate                                                                                                                                                                              NS            
                                                                                                                                                                                                                                     Sub-group analysis: moderately malnourished girls showed shorter duration of hospitalization                                                                                                                                                                                                                                                                                                                 No adjustment for covariates                                                                                            Duration of hospitalization                                                                                                                                                                                              NS            
  Dibley, 1995 \[[@B23]\]              RCT, double-blind                                                                                                                                                                             Pop: 3.4% wasted; 37% stunted                                                                                                                                 Morbidity def: 3+ loose stools per day; time between episodes 2+ diarrhea-free days                                                        Small effect size for acute respiratory infection; large CI for acute lower respiratory infection   Baseline difference in immunization status: ever vaccinated for polio and measles higher in VA group                    VA (n = 396)                                                                                                                           Placebo (n = 386)                                                                              MOD-HIGH
                                       Aim: test efficacy of high-dose VA supplement on acute respiratory and diarrheal illnesses in Indonesian children (6 - 47 mo)                                                                 VA dose: 103,000 IU (\< 1 yr); 206,000 IU (≥ 1 yr)                                                                                                            Acute respiratory episode with 2+ adjoining days for cough; time between episodes of 3+ symptom-free days                                                                                                                                                                                                                                                              **Adverse event risks** Acute respiratory infection                                                                                                                                      rate ratio 1.08 (1.01 - 1.19)                 
                                                                                                                                                                                                                                     **Adverse event risk:** Subgroup analysis showed VA increased diarrhea incidence in children \< 30 mo                                                                                                                                                                                                                                                                                                                                                                                                                                Acute lower respiratory infection                                                                                                                                                        rate ratio 1.39 (1.00 - 1.93)                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Diarrhea                                                                                                                                                                                                                 NS            
  Coutsou-dis, 1991 \[[@B22]\]         RCT, double blind                                                                                                                                                                             VA dose: 54.5 mg (\< 12 mo); 109 mg (\>12 mo)                                                                                                                 Nut def: WAZ by NCHS                                                                                                                       Small sample size                                                                                   Losses to follow-up were 20% at 6 weeks and 40% at 6 months; no characteristics of this group provided                  VA (n = 24)                                                                                                                            Placebo (n = 24)                                                                               MOD
                                       Aim: test efficacy of VAS on measles morbidity in South African children (4 - 24 mo)                                                                                                                                                                                                                                                                        Morbidity def: diarrhea: 3+ loose or watery stools per day; pneumonia: presence of tachypnea with retractions, crackles, wheezes           Statistics: β set to 0.5 only to detect 30% increase in absolute recovery                           No adjustment for covariates; only univariate analyses                                                                  IMS score 0.24 ± 0.15                                                                                                                  IMS score 1.37 ± 0.40                                                             p = 0.037     
                                                                                                                                                                                                                                                                                                                                                                                                   Integrated morbidity score (IMS) used                                                                                                                                                                                                                                                                                                                                  Weight gain at 6 wk 1.29 ± 0.17 kg                                                                                                     Weight gain at 6 wk 0.90 ± 0.14 kg                                                P = 0.04      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Pneumonia recovery 3.8 ± 0.40 d                                                                                                        Pneumonia recovery 5.7 ± 0.79 d                                                   P \< 0.05     
  Hussey, 1990 \[[@B21]\]              RCT, double-blind                                                                                                                                                                             Pop: 70/189 (37%) with WHZ \< 5^th^%                                                                                                                          Nutrition def: percentiles of NCHS standards                                                                                               Rare events: mortality; pneumonia / diarrhea duration ≥10 days                                      Differences in baseline characteristics except rash duration and lower levels of total protein and albumin in placebo   VA (n = 92)                                                                                                                            Placebo (n = 97)                                                                               MOD-HIGH
                                       Aim: test efficacy of high dose VAS on measles complications among hospitalized South African children                                                                                        VA dose: 400,000 IU at admission                                                                                                                                                                                                                                                                                                                                                                             High prevalence of "hyporetinemia" (\< 7.0 μmol /L) 76%                                                                 Pneumonia recovery 6.3 d                                                                                                               Pneumonia recovery 12.4 d                                                         P \< 0.001    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No adjustment for covariates                                                                                            Diarrhea recovery 5.6 d                                                                                                                Diarrhea recovery 8.5 d                                                           P \< 0.001    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Croup 13 cases                                                                                                                         Croup 27 cases                                    0.51 (0.28 - 0.92)              P = 0.01      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Days in hospital 10.6 d                                                                                                                Days in hospital 14.8 d                           0.21 (0.05 - 0.94)                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Mortality 2 deaths                                                                                                                     Mortality 10 deaths                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Risk of death due to major complication                                                                                                                                                  RR 0.51 (0.35, 0.74)                          

The table presents the included RCT studies in the review by date of publication, from most recent to oldest. For each study, the design, aim, quality assessment by GRADE criteria, findings, and GRADE rating are provided.

*Inconsistency* across trials was observed with regards to the ages of children studied, ranging from birth to 14 years. Definitions of morbidity and malnutrition varied, as well as use of differing growth references and standards. Small sample sizes and rare events were the most common problems related to *imprecision*. Despite randomization, several studies also showed significant differences in baseline characteristics that elevated the *risk of bias*. Notably, these included baseline age and nutritional status differences with higher likelihoods of confounding \[[@B28],[@B32],[@B33]\].

Some key findings were identified across trials. First, low-dose VAS conferred more or similar health and recovery advantages when compared to high-dose supplementation in the treatment of malnourished children \[[@B19],[@B26],[@B33]\]. Second, high-dose VAS showed mixed results relative to placebo for infectious disease outcomes in children with and without SAM, showing benefit in some trials for children with severe diarrhea or shigellosis \[[@B27],[@B31]\], measles \[[@B21],[@B22]\], other acute respiratory infections \[[@B30]\], and undifferentiated fever \[[@B24]\]. However, in other trials, there was no benefit for children with acute respiratory infections or diarrhea \[[@B24]-[@B26],[@B29],[@B32]\]. There was also some evidence of improved growth outcomes associated with high-dose VAS among VA deficient children \[[@B20]\] and children with measles \[[@B22]\].

Finally, adverse effects were found to be associated with high-dose VAS in some trials, including an increased rate of respiratory illnesses \[[@B23],[@B28]\] and diarrhea \[[@B26],[@B31]\]. These findings appear primarily in samples or sub-samples of adequately nourished children. As noted previously, we identified only one RCT that included only severely malnourished children \[[@B19]\]. Some explicitly excluded children with marasmus, kwashiorkor, or all children with SAM \[[@B25],[@B27],[@B30],[@B32]\], while the remaining included both malnourished and adequately nourished children. Among the five studies finding adverse events in association with VAS, two of these studies carried out sub-group analyses showing an increased risk of diarrhea among normally nourished children \[[@B31]\] and among children without edema \[[@B26]\]. One trial included only adequately nourished children \[[@B28]\], another found increased risk of ALRI in mainly adequately nourished children \[[@B23]\], and one included both malnourished and adequately nourished children, excluding children with SAM \[[@B32]\]. No adverse effects of the high-dose VAS were found in children with SAM in the trial that replicated the WHO VA guidelines \[[@B19]\].

Discussion
==========

Our systematic review of the literature using the GRADE methodology revealed only limited evidence that directly addresses the safety and effectiveness of high-dose VAS for children with SAM. Fourteen of the 15 RCTs identified for this review included both malnourished and non-malnourished children, thereby complicating the extrapolation of findings directly to efficacy and safety of VAS for SAM. There is sufficient evidence to recommend the use of high-dose VAS for children with SAM when presenting with measles, severe diarrhea (shigellosis), or evidence of VAD. The low-dose VAS regimen should be considered as the preferred protocol in other cases of malnourished children, given the potential for adverse events and similar recovery outcomes when compared to high-dose VAS. Higher quality prospective studies are still needed to directly examine VAD in children with SAM, applying more contemporary definitions of morbidity and malnutrition, and powered sufficiently to detect the critical outcomes of interest.

Observational studies demonstrated an association between SAM and VAD, but metabolic disruptions in SAM might preclude accurate measures of true VA status. Blood biomarkers of retinol concentrations were primarily used to indicate VA status \[[@B14]-[@B16],[@B18]\]. Protein-energy malnutrition has been associated with reduced hepatic synthesis of retinol binding protein (RBP) and transthyretin used to transport VA in the body \[[@B34],[@B35]\]. Thus, VA stores in the liver may not be mobilized appropriately in malnourished children and therefore not be reflected in blood biomarkers. Mitra showed that VA status improved from baseline to hospital discharge, even without VAS \[[@B18]\]. That study also showed that while urinary losses of retinol were associated with low retinol concentrations in children with dysentery, other inflammatory markers such as body temperature and serum α-1-acid glycoprotein and C reactive protein concentrations were more highly and negatively correlated with vitamin A status.

There is some evidence that diarrhea could be mediating this relationship, as revealed by independent associations between diarrhea, low WAZ, and VA levels \[[@B17]\]. Shigellosis*,* in particular, increases the risk of VAD \[[@B18]\]. A study in Brazil showed a possible interaction between SAM and low serum retinol concentrations for higher diarrheal morbidities \[[@B15]\]. Evidence from RCTs also finds that high-dose VAS may be beneficial for treating severely malnourished children in cases of severe diarrhea \[[@B27],[@B31]\]. Again, the mechanism by which VA may be operating to mitigate severe diarrhea in SAM has not been elucidated, but it may be either through the repair of the gut epithelium or immune pathways that restore balance between T-cell subsets \[[@B36]\].

Two studies showed unequivocally the benefit of lose-dose (5000 IU daily until discharge) compared to a single high-dose (200,000 IU for children over 12 months or 100,000 IU for children under 12 months on day 1 of hospitalization) VAS regimen \[[@B26],[@B33]\]. The low-dose regimen was more strongly correlated with lower incidence and shorter duration of respiratory disease \[[@B33]\] and a lower incidence of severe diarrhea \[[@B26]\]. A third study in Bangladesh also examined the administration of a lose-dose protocol in relation to a high-dose on day 1 followed by daily low doses until hospital discharge. \[[@B19]\]. That study did not find any differences in the two groups on a range of morbidity and nutrition recovery outcomes and adverse events. All children at baseline had diarrhea and while clinical signs of VAD were not apparent, baseline measures of VA status did indicate VAD in the sample. With regards to other morbidities, high-dose VAS was effective in reducing measles-specific respiratory illness \[[@B21],[@B22]\], but showed mixed results with regards to non-measles pneumonia and other acute lower respiratory tract infections in children with SAM \[[@B23]-[@B25],[@B28]-[@B30],[@B32],[@B37],[@B38]\].

Only one trial identified in this review specifically included children who were HIV + \[[@B31]\]. Sub-group analyses stratified by HIV status showed a trend towards a protective effect of high-dose VAS on cough and rapid respiratory rate for HIV-infected children \[RR 0.54 (0.24-1.20), p = 0.07\], while children without HIV infection were at increased risk for these conditions \[RR 1.47 (1.16-1.86), p = 0.001\]. Because children infected with HIV are highly vulnerable to SAM and VAD, more research is needed to understand the optimal protocols for this population \[[@B39]\].

The evidence for growth outcomes in the follow-up period from hospital discharge was limited and somewhat dated \[[@B20],[@B22]\]. One study showed that only among children who were VA deficient at baseline were there greater improvements in weight and MUAC in those who received high-dose VAS; this was not evident in the non-VA deficient children and high-dose VAS even reduced height gain among non-VA deficient girls \[[@B20]\]. Standard therapeutic foods designed for growth recovery in SAM may be a safer source of VA in certain cases. The foods contain VA as retinyl acetate, similar to VA supplements, in the following concentrations (per 100 g): F-75, 900 μg; F-100, 800 μg; and RUTF, 800--1100 μg. Thus, for a child weighing 5 kg, this would translate into 1,119 μg/d VA for F-75, or 1,544 μg/d VA for F-100, and 1,680 μg/d VA for RUTF. These quantities are comparable to the low-dose regimen of 5000 IU or 1500 μg retinol and are well below the high-dose recommendation of 100,000 IU or 30,000 μg/d VA that would be given to children under 12 mo. While these foods have not specifically been assessed as alternatives to VAS, the safety and efficacy of these products in the treatment of SAM is well-accepted \[[@B40]-[@B42]\]. Particularly in cases when a child's VA status is unknown or adequate, therapeutic foods could thus serve as the delivery mechanism for low-dose VAS, though more research is needed.

Adverse effects found to be associated with high-dose VAS warrant more research. The most frequent negative outcome was an increased risk of acute respiratory infections \[[@B23],[@B28],[@B31],[@B33]\]. There was also evidence of an increased risk of acute, non-severe diarrhea, mediated in part by nutritional status \[[@B26],[@B31],[@B32]\]. It should be noted that the adverse effects arising from high-dose VAS were found in samples or sub-samples that included primarily adequately nourished children. Heterogeneity in baseline characteristics and study design complicates comparisons across the various studies, but these safety issues should not be ignored. Excessive intake of preformed VA, notably in the absence of dietary fatty acids, may overwhelm the esterification process and introduce more harmful forms of VA into the child's circulation \[[@B6]\]. Further along the metabolic pathway, VA presented to cell membranes in forms other than the RBP complex (as may be the case in SAM) can also lead to significant cellular damage \[[@B43]\]. Carotenoid forms of VA or lipid-based nutrient supplements such as RUTF, should be explored to minimize oxidative stress while still addressing VAD \[[@B44]\].

Conclusions
===========

In the treatment of children with SAM, a high-dose VAS protocol can be safely recommended in cases presenting with measles, severe diarrhea (shigellosis), or symptoms of VAD. More research is needed to study this specific question in populations exclusively malnourished and to understand and prevent adverse outcomes related to high-dose VAS. We recommend exploration of alternative low-dose protocols and strategies beyond VAS, such as use of carotenoids or RUTF interventions, to address VA deficiency and associated health outcomes in the treatment of children with SAM.
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